BR112022024932A2 - Vacina contra vírus da influenza a suína compreendendo um constructo de ácido nucleico que possui uma ordem específica de genes - Google Patents

Vacina contra vírus da influenza a suína compreendendo um constructo de ácido nucleico que possui uma ordem específica de genes

Info

Publication number
BR112022024932A2
BR112022024932A2 BR112022024932A BR112022024932A BR112022024932A2 BR 112022024932 A2 BR112022024932 A2 BR 112022024932A2 BR 112022024932 A BR112022024932 A BR 112022024932A BR 112022024932 A BR112022024932 A BR 112022024932A BR 112022024932 A2 BR112022024932 A2 BR 112022024932A2
Authority
BR
Brazil
Prior art keywords
nucleic acid
acid construct
swine influenza
vaccine
genes
Prior art date
Application number
BR112022024932A
Other languages
English (en)
Inventor
A Mogler Mark
Hangalapura Nagaraj Basav
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of BR112022024932A2 publication Critical patent/BR112022024932A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

VACINA CONTRA VÍRUS DA INFLUENZA A SUÍNA COMPREENDENDO UM CONSTRUCTO DE ÁCIDO NUCLEICO QUE POSSUI UMA ORDEM ESPECÍFICA DE GENES. A presente invenção está relacionada a um construto de ácido nucleico que codifica, nesta ordem, um primeiro antígeno de hemaglutinina (HA) de influenza A suína (IAV-S) da linhagem Scot/94 e um segundo antígeno de hemaglutinina (HA) de influenza A suína (IAV-S) da linhagem tipo ave da Eurásia (EA) e um construto de ácido nucleico que codifica, nesta ordem, um primeiro antígeno de HA de IAV-S da linhagem Gent/84 e um segundo antígeno de HA de IAV-S da linhagem pandemic09 (pdm09). Em outras modalidades, a presente invenção está relacionada a partículas de replicon de RNA compreendendo um ou ambos os construtos de ácido nucleico, uma composição imunogênica, tal como uma vacina, que pode ser usada contra infecções pelo vírus da influenza A e compreende as partículas de replicon. Além disso, são fornecidos métodos para fazer a vacina e o uso da vacina.
BR112022024932A 2020-06-19 2021-06-18 Vacina contra vírus da influenza a suína compreendendo um constructo de ácido nucleico que possui uma ordem específica de genes BR112022024932A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20181094 2020-06-19
PCT/EP2021/066546 WO2021255219A1 (en) 2020-06-19 2021-06-18 Swine influenza a virus vaccine comprising a nucleic acid construct having a specific order of genes

Publications (1)

Publication Number Publication Date
BR112022024932A2 true BR112022024932A2 (pt) 2022-12-27

Family

ID=71170243

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024932A BR112022024932A2 (pt) 2020-06-19 2021-06-18 Vacina contra vírus da influenza a suína compreendendo um constructo de ácido nucleico que possui uma ordem específica de genes

Country Status (6)

Country Link
US (2) US12630592B2 (pt)
EP (1) EP4168041A1 (pt)
JP (1) JP7767328B2 (pt)
CN (1) CN115768472A (pt)
BR (1) BR112022024932A2 (pt)
WO (1) WO2021255219A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230248817A1 (en) * 2020-06-19 2023-08-10 Intervet Inc. Swine influenza a virus vaccine comprising a nucleic acid construct comprising first, second and third nucleic acid sequences encoding distinct neuraminidase antigens of the virus
EP4168044A1 (en) 2020-06-19 2023-04-26 Intervet International B.V. Swine influenza a virus vaccine comprising two distinct rna replicon particles

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1751289E (pt) 2004-05-18 2009-03-31 Alphavax Inc Vectores de alfavirais derivados da tc-83, partículas e métodos
DK2947149T3 (en) * 2007-06-21 2018-06-06 Alphavax Inc ALPHAVIRUS REPLICATION PARTICLES FOR USE IN VACCINATION
TWI551295B (zh) 2008-04-18 2016-10-01 英特威特國際股份有限公司 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）用疫苗
TWI449533B (zh) 2008-04-18 2014-08-21 Intervet Int Bv 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａ ｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅ ｃｉｒｃｏ ｖｉｒｕｓ）用疫苗
RU2451027C2 (ru) 2010-05-27 2012-05-20 Общество с ограниченной ответственностью "Нанолек" Рекомбинантная вакцина против вируса "свиного" гриппа h1n1 и спсоб ее получения
EP2721158B1 (en) 2011-06-20 2017-05-03 University of Pittsburgh - Of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for h1n1 influenza
UY37408A (es) 2016-09-20 2018-03-23 Boehringer Ingelheim Vetmedica Gmbh Vacuna de vectores contra el virus de la gripe “a” porcina
KR20190093816A (ko) 2016-10-26 2019-08-26 큐어백 아게 지질 나노입자 mRNA 백신
EP3727444A1 (en) 2017-12-18 2020-10-28 Intervet International B.V. Swine influenza a virus vaccine
RU2706191C1 (ru) 2018-12-28 2019-11-14 Общество с ограниченной ответственностью "Нанолек" Поливалентная вакцина против гриппа

Also Published As

Publication number Publication date
WO2021255219A1 (en) 2021-12-23
US12630592B2 (en) 2026-05-19
JP7767328B2 (ja) 2025-11-11
US20260217771A1 (en) 2026-07-30
JP2023530133A (ja) 2023-07-13
EP4168041A1 (en) 2023-04-26
US20230265130A1 (en) 2023-08-24
CN115768472A (zh) 2023-03-07

Similar Documents

Publication Publication Date Title
Chivukula et al. Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza
PE20250020A1 (es) Composicion inmunogenica contra la influenza
BR112022026733A2 (pt) Imunógenos estabilizados de proteína spike (s) de coronavírus e vacinas relacionadas
BR112023005674A2 (pt) Construtos anti-cd93 e usos dos mesmos
MX2022009429A (es) Composiciones para la inmunizacion contra virus respiratorios.
BR112022025733A2 (pt) Vetores hvt recombinantes expressando hemaglutinina de influenza e composições imunogênicas, e produção e usos dos mesmos
MX340880B (es) Vacunas mejoradas y metodos para uso de las mismas.
AR068507A1 (es) Construcciones vector fluorocarbonado-antigeno para el suministro de antigenos ifluenza
CL2018003178A1 (es) Composición farmacéutica
CY1118080T1 (el) Σωματιδια απελευθερωσης που ομοιαζουν με ιικα σωματιδια για αυτοαντιγραφικα rna μορια
MX2025003572A (es) Vacunas contra el virus de la influenza
BR112012008000A2 (pt) excipiente estabilzante para vacina com vírus plenos inativados
MX2022012251A (es) Vacuna universal contra la influenza usando arnm modificado con nucleósidos.
BR112019009133A2 (pt) vacina contra o parvovírus suíno
BR112022024629A2 (pt) Construtos anti-cd93 e seus usos
NO20082149L (no) Hundeinfluensavirus og relaterte sammensetninger og fremgangsmater for bruk
UY31569A1 (es) Vacunas contra la malaria
CL2020001901A1 (es) Vacunas contra virus de la gripe y usos de las mismas.
BR112022022859A2 (pt) Vacinas contra sars-cov-2
MX2022002766A (es) Vacunas contra el virus de la gripe y usos de las mismas.
MX383416B (es) Nueva vacuna contra la influenza porcina.
CL2025001619A1 (es) Nanopellets de proteína para la vacunación de peces o teleósteos y crustáceos
BR112022025678A2 (pt) Vacina contra o vírus da influenza a suína compreendendo duas partículas de replicon de rna distintas
MX2024005482A (es) Vacunas hibridas multivalentes antigripales que comprenden hemaglutinina y neuraminidasa y metodos de uso de las mismas.
Zhu et al. A Modular Bacteriophage T4 Nanoparticle Platform Enables Rapid Design of Dual COVID‐19‐Flu Mucosal Vaccines